Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).

Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020.

J Clin Oncol 38 no. 15_suppl (May 20, 2020) 8060-8060. DOI: 10.1200/JCO.2020.38.15_suppl.8060

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
REFLECT
2020
Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study.

Dechow T, Riera-Knorrenschild J, Hackanson B, Fischer von Weikersthal L, Schulz H, Chiabudini M, Timm B, Zerbes R, Potthoff K, 2020.

J Clin Oncol 38: 2020 (suppl; abstr e21611) doi: 10.1200/JCO.2020.38.15_suppl.e21611

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
NEPTUN
2020
Dynamics in the choice of treatment for patients with Multiple Myeloma – Results from the MYRIAM registry.

Engelhardt, M., Knauf, W., Lipke, J., Reiser, M., Dörfel, S., Kortüm, M., Schlag, R., von der Heyde, E., La Rosée, P., Pfannes, R., Lamberti, C., Houet, L., Medinger, T., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2020.

HemaSphere 4(S1)(EP994), 454–455.

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: EHA / Journal: HemaSphere
MYRIAM
2020
Effectiveness and Tolerability of Nab-Paclitaxel in Younger versus Elderly Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO

Potthoff, Karin, Oliver Stötzer, Ulrike Söling, Richard Hansen, Johanna Harde, Stephanie Dille, Arnd Nusch, und Norbert Marschner, 2020.

Clinical Breast Cancer 20, Nr. 3 (1. Juni 2020): e315–26 https://doi.org/10.1016/j.clbc.2019.11.003

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Clinical Breast Cancer
NABUCCO
2020
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.

Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K, 2020.

BMC Cancer. 2020 Apr 6;20(1):286. doi: 10.1186/s12885-020-06747-y.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: BMC Cancer
IMPROVE
2020
Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer

Marschner, N., Zacharias, S., Lordick, F., Hegewisch-Becker, S., Martens, U., Welt, A:, Hagen, V., Gleiber, W., Bohnet, S., Kruggel, L., Dille, S., Nusch, A., Dörfel, S., Decker, T., Jänicke, M.

JAMA Network Open 3, Nr. 3 (2. März 2020): e200643–e200643. https://doi.org/10.1001/jamanetworkopen.2020.0643

Indikation: Breast Cancer, Colorectal Cancer, Kolorektalkarzinom, Lung Cancer, Lungenkarzinom, Mammakarzinom, Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: - / Journal: Jama Network Open
Indikationsübergreifend
2020
Clinical reserach platform into molecular testing, treatment and outcome of NSCLC (CRISP)

F. Griesinger, 2020.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CRISP
2020
Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany.

Goebell, P.J., Grüllich, C., Reichert, D., Bögemann, M., Dörfel, S., von der Heyde, E., Binninger, A., Jänicke, M., Marschner, N., Staehler, M., Grünwald, V., 2020.

Oncol Res Treat 43 (suppl 1)(391), 76.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CARAT
2020
Molekulare Testung von Patienten mit EGFR-Mutations-positivem lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligen Lungenkarzinom im Behandlungsalltag – Aktualisierte Zwischenergebnisse der Registerstudie PANORAMA.
Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
PANORAMA
2020
Nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC in the real-world setting: Safety results of the non-interventional NEPTUN study.

Dechow, T., Riera-Knorrenschild, J., Hackanson, B., Fischer von Weikersthal, L., Chiabudini, M., Timm, B., Zerbes, R.M., Potthoff, K., 2020.

Oncol Res Treat 43 (suppl 1)(276), 112.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
NEPTUN
2020